International rare disease opportunities require more than market entry.
For biotech companies developing therapies for rare and ultra-rare diseases, international expansion is not simply a commercial decision. It requires clinical credibility, regulatory understanding, patient identification, local medical engagement, data generation and a clear strategy for responsible access. Pharma²⁸ helps biotech companies evaluate, structure and activate opportunities in Brazil and other international markets, starting with a strong clinical and strategic foundation.
Pharma²⁸ works with biotech companies seeking to understand whether Brazil or other international markets may be relevant for their rare disease programs.
We support companies across key areas:
Rare disease opportunity assessment
Where a therapy may be clinically and strategically relevant.
Clinical and medical feasibility
Investigators, centers and patient populations.
Brazil market-entry strategy
Clinical, regulatory, institutional and access planning.
Regulatory pathway support
Studies, early access, evidence and registration.
Physician and center-of-excellence engagement
Trusted relationships with disease-area experts.
Patient identification and diagnostic intelligence
Where relevant patients may be concentrated.
Real-world evidence and data-generation planning
Local data supporting development decisions.
Early access and compassionate-use strategy
Responsible pathways aligned with medical need.
Strategic partnerships
Medical, institutional and patient-access stakeholders.
Not only market entry — a clinical development advantage.
Brazil is not only a market-entry opportunity. It can also become a clinical development advantage.
For selected rare and ultra-rare disease programs, Brazil may offer access to deep patient cohorts, high-volume expert centers, experienced investigators, academic research infrastructure, real-world clinical experience and public or institutional research pathways aligned with unmet medical needs.
The challenge is that these assets are fragmented. Biotech companies often need a trusted partner able to connect clinical expertise, regulatory strategy, patient identification, institutional relationships and data intelligence into one practical pathway. That is the role Pharma²⁸ plays.
Rare disease therapies often face a common international challenge: patients may exist in meaningful numbers, but they are difficult to identify, diagnose, refer and connect to appropriate clinical or therapeutic pathways.
Pharma²⁸ helps address this gap by combining medical expertise, curated disease evidence, market intelligence, physician networks and AI-enabled data infrastructure. This allows biotech companies to better understand where their therapies may have clinical relevance, where patient populations may be found and where international development can create long-term value.
Brazil is one of the most important healthcare markets outside the United States, with a single-market population of more than 200 million people, advanced academic and clinical centers, experienced specialists and increasing demand for innovative therapies in rare and ultra-rare diseases.
For biotech companies, Brazil may offer opportunities for:
Clinical collaboration
Alignment with credible investigators and institutions.
Patient identification
Access to deep and diverse patient cohorts.
Regulatory development
Structured pathways aligned with local expertise.
Real-world evidence generation
Data from advanced clinical environments.
Early access programs
Responsible pathways for high-need therapies.
Partnerships with leading physicians and institutions
Trusted long-term collaboration.
Long-term commercial and access strategy
A single pathway into one of the world's largest markets.
Strategic alignment first.
Before pursuing any market-entry or access pathway, Pharma²⁸ evaluates the therapy, disease area, clinical context, potential patient population, regulatory considerations, physician ecosystem and strategic relevance of the opportunity.
From there, we help structure a responsible path forward — one that aligns the interests of biotech companies, physicians, institutions, patients and local healthcare stakeholders.
Rare and ultra-rare diseases require a different operating model. Traditional market access is often not enough. These programs require stronger diagnostic intelligence, specialist engagement, evidence mapping, patient journey understanding and local clinical validation.
Pharma²⁸ provides a specialized platform for biotech companies working in complex, high-need therapeutic areas where precision, credibility and strategic execution matter.
If your company is developing a therapy for a rare or ultra-rare disease and is considering international clinical, regulatory, data or patient-access opportunities, Pharma²⁸ can help assess whether Brazil or other markets should be part of your strategic path.
We welcome conversations with biotech companies, clinical development teams, medical affairs leaders, business development executives and strategic partners exploring responsible international growth.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.